A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 861 participants.

Also called NCT03990363

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 861 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03990363
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, France, Hungary, Israel, Italy, Mexico, Poland, Romania, Slovakia, South Africa, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03990363. Randomized; quadruple masking; primary purpose treatment. Start 2019-07-23 (actual); primary completion 2021-11-22 (actual). Results posted on 2023-03-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
Acronym
SAPPHIRE
Intervention (Drug)
Verinurad
Intervention (Drug)
Allopurinol
Intervention (Drug)
Placebo for Verinurad
Intervention (Drug)
Placebo for Allopurinol
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct03990363
Content hash
546e101a5a4820f5a90f776e8bcaf4e2c04985b617aa3bbcf83a8ee487494fb0